Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 14/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 11/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13153912 | 0.84 | CYP2C9 (0.42) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL15025464 | 0.81 | CYP2C9 (0.38) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL15428830 | 0.79 | PTGDR2 (0.53) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3088522 | 0.78 | PTGDR2 (0.64) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3095939 | 0.76 | PTGDR2 (0.47) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL12017276 | 0.75 | CYP2C9 (0.37) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL15428828 | 0.75 | PTGDR2 (0.60) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL12002786 | 0.74 | CYP2C9 (0.36) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL3097129 | 0.72 | PTGDR2 (0.61) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3102600 | 0.69 | PTGDR2 (0.52) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017005764-A1 | A PROCESS TO MAKE TRICYCLOKETONE INTERMEDIATES OF CRTH2 ANTAGONISTS | INTERVET INTERNATIONAL B.V. (NL) | 2017-01-12 | — | — | WO | disclosed |
| EP-2492267-B1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2401269-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8394819-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2492267-A1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | PTGDR2 2/4885PTGDR 3/4885TBXA2R 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.